Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: Results from the CO-MED trial

European Neuropsychopharmacology

Volumn 22, Issue 3, 2012, Pages 183-199

  Friedman, Edward S ^a   Davis, Lori L ^b,c   Zisook, Sidney ^d,e   Wisniewski, Stephen R ^f   Trivedi, Madhukar H ^g   Fava, Maurizio ^h   Rush, A John ⁱ  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^f UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Abuse; Combination treatment severity; Depression; Remission; Response; Suicide

Indexed keywords

AMFEBUTAMONE; ESCITALOPRAM; MIRTAZAPINE; PLACEBO; VENLAFAXINE;

16 ITEM QUICK INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY SELF REPORT; ADULT; AFRICAN AMERICAN; AGED; AGORAPHOBIA; ANXIETY; ARTICLE; BODY MASS; BULIMIA; CHILD ABUSE; CHILD NEGLECT; CLINICAL ASSESSMENT TOOL; CLINICAL EFFECTIVENESS; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG ABUSE; DRUG DOSE INCREASE; EDUCATION; EMPLOYMENT; EUROPEAN AMERICAN; FEMALE; GENDER; GENERALIZED ANXIETY DISORDER; GROUPS BY AGE; HISPANIC; HUMAN; HYPOCHONDRIASIS; INCOME; INSOMNIA; IRRITABILITY; LONELINESS; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MANIA; MENOPAUSE; MENTAL PATIENT; MONOTHERAPY; ONSET AGE; OUTPATIENT; PANIC; POSTTRAUMATIC STRESS DISORDER; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RACE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SEXUAL ABUSE; SINGLE BLIND PROCEDURE; SOCIAL PHOBIA; SOMATOFORM DISORDER; SUBSTANCE ABUSE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE ATTEMPT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; BUPROPION; CITALOPRAM; CYCLOHEXANOLS; DEPRESSIVE DISORDER; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIANSERIN; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; SUICIDE; TREATMENT OUTCOME;

EID: 84856514022     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2011.07.010     Document Type: Article

References (45)

1. Altman E.G., Hedeker D., Peterson J.L., Davis J.M. The Altman Self-Rating Mania Scale. Biol. Psychiatry 1997, 42(10):948-955.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatric Press, Washington DC, text revision. 4th ed.
3. Bradvik L., Mattison C., Bogren M., Nettelbladt P. Long-term suicide risk of depression in the Lundby cohort 1947-1997 - severity and gender. Acta Psychiatr Scand 2008, 117:185-191.
4. Brown C., Schulberg H.C., Prigerson H.G. Factors associated with symptomatic improvement and recovery from major depression in primary care patients. Gen Hosp Psychiatry 2000, 22:242-250.
5. Chen L.P., Murad M.H., Paras M.L., Colbenson K.M., et al. Sexual abuse and lifetime diagnosis of psychiatric disorders: systematic review and meta-analysis. Mayo Clin Proc 2010, 85(7):618-629. Epub 2010 May 10.
6. Dunlop B.W., Li T., Kornstein S.G., Friedman E.S., et al. Correlation between patient and clinician assessments of depression severity in the PREVENT study. Psychiatr. Res. 2010, 177:177-183.
7. Elkin I., Gibbons R.D., Shea T.M., Sotski S.M., et al. Initial severity and differential treatment outcome in the National Institute of Mental Health Treatment of Depression Collaborative Research Program. J Consult Clin Psychol 1995, 63:841-847.
8. Fava M. Augmentation and combination strategies in treatment-resistant depression. J. Clin. Psychiatry 2001, 62(Suppl 18):4-11.
9. Fava M., Iosifescu D.V., Pedrelli P., Baer L. Reliability and validity of the Massachusetts general hospital cognitive and physical functioning questionnaire. Psychother Psychosom 2009, 78(2):91-97. Epub 2009 Feb 13.
10. Fournier J.C., Derubeis R.J., Hollon S.D., DImidjian S., et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. J Am Med Assoc 2010, 303(1):47-53.
11. Frisch M.B. Manual and Treatment Guide for the Quality of Life Inventory 1994, National Computer Systems, Inc., Minneapolis, MN.
12. Frisch M.B., Clark M.P., Rouse S.V., Rudd M.D., et al. Predictive and treatment validity of life satisfaction and the quality of life inventory. Assessment 2005, 12(1):66-78.
13. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-61.
14. Hollon S.D., DeRubeis R.J., Evans M., Weimer M.J., et al. Cognitive therapy and pharmacotherapy for depression: singly and in combination. Arch. Gen. Psychiatry 1992, 49:774-781.
15. Joffe R.T., Young T., Leavitt A.J., MacQueen G., et al. Number of episodes and antidepressant response in major depression. Int J Neuropsychopharmacology 1999, 2:111-113.
16. Khan A., Leventhal R.M., Khan S.R., Brown W.A. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol 2002, 22(1):40-45.
17. Kirsch I., Deacon B.J., Huedo-Medina T.B., Scoboria A., et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008, 5(2):e45.
18. Leuchter A.F., Lesser I.M., Trivedi M.H., Rush A.J., et al. An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder. J Psychiatr Pract 2008, 14(5):271-280.
19. Levine J., Schooler N.R. SAFTEE. A technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 1986, 22(2):343-381.
20. Levine J., Schooler N.R. General versus specific inquiry with SAFTEE. J Clin Psychopharmacol 1992, 12(6):448.
21. McGrath P.J., Stewart J.W., Fava M., Trivedi M.H., et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am. J. Psychiatry 2006, 163(9):1531-1541.
22. Mundt J.C., Marks I.M., Shear M.K., Greist J.H. The Work and Social Adjustment Scale: a simple measure of impairment in functioning. Br J Psychiatry 2002, 180:461-464.
23. Nemeroff C.B., Heim C.M., Thase M.E., Klein D.N., et al. Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc. Natl. Acad. Sci. USA 2003, 100(24):14,293-14,296. Epub 2003 Nov 13.
24. Papakostas G.I., Petersen T.J., Kinrys G., Burns A.M., et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J. Clin. Psychiatry 2005, 66(10):1326-1330.
25. Reilly M.C., As Zbrozek, Dukes E.M. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 1993, 4(5):353-365.
26. Robins E. Suicide 1986, 123-133. Williams & Wilkins, Baltimore, MD. A. Roy (Ed.).
27. Rush A.J., Gullion C.M., Basco M.R., Jarrett R.B., et al. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med 1996, 26(3):477-486.
28. Rush A.J., Carmody T.J., Reimitz P.E. The Inventory of Depressive Symptomatology (IDS): clinician (IDS-C) and self-report (IDS-SR) ratings of depressive symptoms. Int J Methods Psychiatr Res 2000, 9:45-59.
29. Rush A.J., Trivedi M.H., Ibrahim H.M., Carmody T.J., et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol. Psychiatry 2003, 54(5):573-583. Erratum p. 585.
30. Rush A.J., Zimmerman M., Wisniewski S.R., Fava M., et al. Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features. J Affect Disord 2005, 87(1):43-55.
31. Rush A.J., Bernstein I.H., Trivedi M.H., Carmody T.J., et al. An evaluation of the Quick Inventory of Depressive Symptomatology and the Hamilton Rating Scale for Depression: a Sequenced Treatment Alternatives to Relieve Depression trial report. Biol. Psychiatry 2006, 59(6):493-501. Epub 2005 Sep 30.
32. Rush A.J., Trivedi M.H., Stewart J.W., Nierenberg M.D., et al. Combining medications to enhance depression outcomes (CO-MED): Acute and long-term outcomes of a single-blind randomized study. Am. J. Psychiatry 2011, 168(7):689-701.
33. Sangha O., Stucki G., Liang M.H., Fossel Ah., et al. The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum 2003, 49(2):156-163.
34. Tedlow J., Fava M., Uebelacker L., Nierenberg A.A., et al. Outcome definitions and predictors in depression. Psychother Psychosom 1998, 67:226-270.
35. Trivedi M.H., Daly E.J. Measurement-based care for refractory depression: a clinical decision support model for clinical research and practice. Drug Alcohol Depend 2007, 88(Suppl 2):S61-S71.
36. Trivedi M.H., Rush A.J., Ibrahim H.M., Carmody T.J., et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med 2004, 34(1):73-82.
37. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 2006, 163(1):28-40.
38. Trivedi M.H., Rush A.J., Gaynes B.N., Stewart J.W., et al. Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR*D measurement-based care. Neuropsychopharmacology 2007, 32(12):2479-2489.
39. Trivedi M.H., Wisniewski S.R., Morris D.W., et al. The concise health risk tracking scale: a brief self-report and clinician rating of suicidal risk. J. Clin. Psychiatry 2011, 72(6):757-764.
40. Vallejo J., Gasto C., Catalan R., Bulbena A., et al. Predictors of antidepressant treatment outcome in melancholia: psychosocial, clinical and biological indicators. J Affect Disord 1991, 21:151-162.
41. Van H.L., Schoevers R.A., Dekker J. Predicting the outcome of antidepressants and psychotherapy for depression: a qualitative, systematic review. Harv Rev Psychiatry 2008, 16:225-234.
42. Wisniewski S.R., Eng H., Meloro L., Gatt R., et al. Web-based communications and management of a multi-center clinical trial: the Sequenced Treatment Alternatives to Relieve (STAR*D) project. Clinical Trials 2004, 1(4):387-398.
43. Wisniewski S.R., Rush A.J., Balasubramani G.K., Trivedi M.H., et al. Self-rated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract 2006, 12(2):71-79.
44. Zimmerman M., Mattia J.I. A self-report scale to help make psychiatric diagnoses: the Psychiatric Diagnostic Screening Questionnaire. Arch. Gen. Psychiatry 2001, 58(8):787-794.
45. Zimmerman M., Mattia J.I. The Psychiatric Diagnostic Screening Questionnaire: development, reliability and validity. Compr Psychiatry 2001, 42(3):175-189.